骨化三醇联合厄贝沙坦治疗对早期2型糖尿病肾病患者肾间质纤维化的影响

Effect of calcitriol combined with irbesartan on renal interstitial fibrosis in patients with early type 2 diabetic nephropathy

目的:探讨骨化三醇联合厄贝沙坦治疗在早期2型糖尿病肾病患者中的应用效果。方法:选取2023年1月至2023年12月我院收治的80例早期2型糖尿病肾病患者,根据随机数表法随机分为两组,每组各40例。对照组口服厄贝沙坦150 mg治疗,观察组口服骨化三醇0.25μg联合厄贝沙坦150 mg治疗。治疗2 m后,采用血糖分析仪检测其餐后2 h血糖(2 hour postprandial blood glucose,2hPBG)、空腹血糖(fasting blood glucose,FBG)、糖化血红蛋白(HemoglobinA1c,HbA1c);以酶联免疫吸附法检测血管内皮生长因子(Vascular endothelial growth factor,VEGF)、血清同型半胱氨酸(Homocysteine,Hey)、转化生长因子β1(Transforming growth factor-β1,TGF-β1)水平;观察患者治疗效果及记录不良事件发生率。结果:观察组的治疗效果显著高于对照组(P<0.05)。观察组Hcy、VEGF、TGF-β1各项肾间质纤维化指标水平均显著低于对照组(P<0.05)。观察组的FBG、2hPBG、HbA1c各项血糖水平均显著低于对照组(P<0.05)。观察组的不良反应发生率与对照组比较无显著差异(P>0.05)。结论:骨化三醇联合厄贝沙坦治疗能改善患者肾间质纤维化,且安全性较好。

Objective:To explore the effect of calcitriol combined with irbesartan in the treatment of early type 2 diabetes nephropathy.Methods:From January 2023 to December 2023,80 patients with early type 2 diabetes nephropathy admitted to our hospital were randomly divided into two groups according to the random number table,with 40 patients in each group.The control group was treated with 150 mg of irbesartan orally,while the observation group was treated with 0.25μg of calcitriol orally combined with Irbesartan 150 mg for treatment.After 2 months of treatment,the 2-hour postprandial blood glucose(2hPBG),fasting blood glucose(FBG),and glycated hemoglobin(HbA1c)were measured using a blood glucose analyzer.The levels of vascular endothelial growth factor(VEGF),serum homocysteine(Hey),and transforming growth factor(TGF-β1)were measured by the enzyme-linked immunosorbent assay.The treatment effect of patients and the incidence of adverse events were recorded.Results:The therapeutic effect of the observation group was significantly higher than that of the control group(P<0.05).The levels of Hcy,VEGF,and TGF-β1 in the observation group were significantly lower than those in the control group(P<0.05).The levels of FBG,2hPBG,and HbA1c in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:The combination of calcitriol and irbesartan can improve renal interstitial fibrosis in patients with good safety.